Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Braicu, David Cibula, Nicoletta Colombo, Jean Sebastien Frenel, Flora Zagouri, Vittoria Carbone, Viola Ghizzoni, Serena Giolitto, Elena Giudice, Maria Teresa Perri, Caterina Ricci, Giovanni Scambia, Domenica Lorusso
International Journal of Gynecologic Cancer Oct 2021, 31 (10) 1369-1373; DOI: 10.1136/ijgc-2021-002593